[The effect of buserelin therapy in endometriosis].
We have treated 31 patients for 6 months at the UFK Tübingen. The AFS-score declined from 7.3 to 3.6, and the--for adhesions corrected--implantation-score from 3.5 to 0.5. Last decline was statistically significant. The endometriosis-specific symptoms disappeared almost completely under Buserelin-therapy. Therapeutic concentrations of E2 (less than 55 pg/ml) were achieved after 4 weeks of therapy. Vaginal bleeding occurred in the first month in 48%, in the second month in 9%, and in the following month in 6% of our patients. With respect to weight, blood pressure, cholesterol, triglycerides, GOT, GPT, and calcium, there were no statistically significant changes before an after buserelin-therapy for 6 months. The pregnancy rate was, so far, 31%, and the reappearance of clinical symptoms occurred in 6.5%.
Fuchs
U
U
Universitäts-Frauenklinik Tübingen.
D000281:Administration, Intranasal; D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D010535:Laparoscopy; D008875:Middle Aged
D002064:Buserelin
Wirkung der Buserelintherapie bei Endometriose.